Trials / Completed
CompletedNCT00122317
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 187 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
Detailed description
An open-label extension study to evaluate long-term safety of eculizumab in PNH patients who had completed the TRIUMPH (C04-001), SHEPHERD (C04-002), and X03-001 studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | eculizumab |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2008-09-01
- Completion
- 2008-10-01
- First posted
- 2005-07-22
- Last updated
- 2018-03-13
- Results posted
- 2017-06-05
Locations
40 sites across 12 countries: United States, Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00122317. Inclusion in this directory is not an endorsement.